



(51) International Patent Classification:

A61K 38/37 (2006.01) A61K 48/00 (2006.01)
A61K 45/06 (2006.01) C07K 14/755 (2006.01)

(21) International Application Number:

PCT/US2018/044892

(22) International Filing Date:

01 August 2018 (01.08.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/540,053	01 August 2017 (01.08.2017)	US
62/583,890	09 November 2017 (09.11.2017)	US
62/596,535	08 December 2017 (08.12.2017)	US
62/596,670	08 December 2017 (08.12.2017)	US

(71) Applicant: SPARK THERAPEUTICS, INC. [US/US];
3737 Market Street, Suite 1300, Philadelphia, Pennsylvania
19104 (US).


(72) Inventor: ANGUELA, Xavier; 3737 Chestnut Street, Apt.
1404, Philadelphia, Pennsylvania 19104 (US).

(74) Agent: BEDGOOD, Robert M.; PILLSBURY WIN-
THROP SHAW PITTMAN LLP, P.O. BOX 10500,
McLean, Virginia 22102 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: FACTOR VIII (FVIII) GENE THERAPY METHODS

Figure 16



(57) Abstract: Methods of using v-vectors comprising nucleic acid and nucleic acid variants encoding FVIII protein are disclosed. In particular embodiments, a method of treating a human having hemophilia A includes administering a recombinant adeno-associated virus (rAAV) vector comprising a nucleic acid encoding Factor VIII (FVIII) or nucleic acid variant encoding Factor VIII (FVIII) having a B domain deletion (hFVIII-BDD). In some aspects, a nucleic acid variant has 95% or greater identity to SEQ ID NO:7 and/or a nucleic acid variant has no more than 2 cytosine-guanine dinucleotides (CpGs). In other aspects, a rAAV vector is administered to the human at a dose of less than about 6×10^{12} vector genomes per kilogram (vg/kg).

[Continued on next page]

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*